読み込み中
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
前日終値
$8.40
+$0.14 · +1.69%
日中の時刻はETです。市場データは遅延する場合があります。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日中レンジ
現在 $8.40
52週レンジ
現在 $8.40
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
51
適正価値
センチメント
62
強気
リスク
42
やや高いリスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日中レンジ
現在 $8.40
52週レンジ
現在 $8.40
| 指標（USD） | 2025年度 |
|---|---|
| 売上高 | 1861.8万 USD |
| 粗利益 | 1861.8万 USD |
| 研究開発 | 5375.6万 USD |
| 販売・一般管理 | 4167.6万 USD |
| 営業費用 | 9543.2万 USD |
| 減価償却費と償却費 | 32.3万 USD |
| 営業利益 | −7681.4万 USD |
| 純利益 | −7668.4万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI690.53万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM318.49万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF251.25万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO109.95万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO81.04万0.01%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA71.3万0.00%218.24億 USD0.03%$32.79+0.40%
iShares Micro-Cap ETFIWC38.72万0.03%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17万0.14%1.17億 USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
